[CAR-T therapy in relapsed or refractory B-cell acute lymphoblastic leukemia: a new treatment paradigm.]

The therapy of patients with acute lymphoblastic leukemia (ALL) in the latter has achieved significant progress by increasing the complete remission (CR) rate, re-binding allogeneic transplantation to patients with high-risk disease and/or not in MRD…

Preview only. Read the full abstract at the source